(Nevada, USA) DelveInsight’s “Chronic Spontaneous Urticaria Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Chronic Spontaneous Urticaria market share of the individual therapies, current and forecasted Chronic Spontaneous Urticaria market size from 2019 to 2032 segmented by seven major markets. The report also offers current Chronic Spontaneous Urticaria therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Chronic Spontaneous Urticaria market.
Chronic Spontaneous Urticaria Overview
Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or “wheals” on the skin. It is being associated with autoimmunity in almost half of the cases, but the remaining cases still remain “idiopathic,” and all are considered spontaneous. Therefore, the term chronic spontaneous urticarial (CSU) has been employed to indicate chronic urticaria that is endogenous and is independent of any external physicalstimulus, which is conceptually helpful and does not imply knowing or not-knowing the cause.
Some of the key facts of the Chronic Spontaneous Urticaria Market Report:
• The Chronic Spontaneous Urticaria market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As per a study by T. Zuberbier et al., the life-time prevalence for any subtype of urticaria is approximately 20%
• As per a study by Napolitano et al., the prevalence of Chronic urticaria (CU) in adults is estimated at 0.5% to 5%, while it affects 0.1% to 3% of children
• Key Chronic Spontaneous Urticaria Companies: Novartis, Genentech, United BioPharma, and others
• Key Chronic Spontaneous Urticaria Therapies: Ligelizumab, Remibrutinib, MTPS9579A, UB-221, and others
• The Chronic Spontaneous Urticaria epidemiology based on gender analyzed that Chronic Spontaneous Urticaria is more prominent in females in comparison to males
Chronic Spontaneous Urticaria Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Discover more about Chronic Spontaneous Urticaria therapies in the pipeline @ Chronic Spontaneous Urticaria Drugs
Chronic Spontaneous Urticaria Therapies and Key Companies
• Ligelizumab: Novartis
• Remibrutinib: Novartis
• MTPS9579A: Genentech
• UB-221: United BioPharma
Chronic Spontaneous Urticaria Market Drivers
• Treatment Side Effects With Currently Available Chronic Spontaneous Urticaria Treatment
• Economic Burden On Patients
• Increase in Research and Development Activities
• Increasing Chronic Spontaneous Urticaria Market Size
Chronic Spontaneous Urticaria Market Dynamics
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Spontaneous Urticaria market or expected to get launched during the study period. The analysis covers Chronic Spontaneous Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Spontaneous Urticaria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn more about the recent developments and breakthroughs in the Chronic Spontaneous Urticaria market @ Chronic Spontaneous Urticaria Clinical Trials
Scope of the Chronic Spontaneous Urticaria Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
• Key Chronic Spontaneous Urticaria Companies: Novartis, Genentech, United BioPharma, and others
• Key Chronic Spontaneous Urticaria Pipeline Therapies: Ligelizumab, Remibrutinib, MTPS9579A, UB-221, and others
• Chronic Spontaneous Urticaria Therapeutic Assessment: Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
• Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria market drivers and Chronic Spontaneous Urticaria market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Chronic Spontaneous Urticaria Market entry strategies
• Chronic Spontaneous Urticaria Unmet Needs, KOL’s views, Analyst’s views, Chronic Spontaneous Urticaria Market Access and Reimbursement
Table of Contents
1. Chronic Spontaneous Urticaria Market Key Insights
2. Chronic Spontaneous Urticaria Market Report Introduction
3. Chronic Spontaneous Urticaria Market Overview at a Glance
4. Chronic Spontaneous Urticaria Market Executive Summary
5. Disease Background and Overview
6. Chronic Spontaneous Urticaria Treatment and Management
7. Chronic Spontaneous Urticaria Epidemiology and Patient Population
8. Patient Journey
9. Chronic Spontaneous Urticaria Emerging Drugs
10. 7MM Chronic Spontaneous Urticaria Market Analysis
11. Chronic Spontaneous Urticaria Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Chronic Spontaneous Urticaria Market Drivers
15. Chronic Spontaneous Urticaria Market Barriers
16. Chronic Spontaneous Urticaria Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Gaurav Bora
info@delveinsight.com
+1(919)321-6187
